These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 24710307)

  • 1. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
    Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
    Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
    Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
    Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
    Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF
    Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.
    Gay LM; Kim S; Fedorchak K; Kundranda M; Odia Y; Nangia C; Battiste J; Colon-Otero G; Powell S; Russell J; Elvin JA; Vergilio JA; Suh J; Ali SM; Stephens PJ; Miller VA; Ross JS
    Oncologist; 2017 Jul; 22(7):834-842. PubMed ID: 28495808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance of genomic alterations between primary and recurrent breast cancer.
    Meric-Bernstam F; Frampton GM; Ferrer-Lozano J; Yelensky R; Pérez-Fidalgo JA; Wang Y; Palmer GA; Ross JS; Miller VA; Su X; Eroles P; Barrera JA; Burgues O; Lluch AM; Zheng X; Sahin A; Stephens PJ; Mills GB; Cronin MT; Gonzalez-Angulo AM
    Mol Cancer Ther; 2014 May; 13(5):1382-9. PubMed ID: 24608573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative genomic analysis of primary tumors and metastases in breast cancer.
    Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
    Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
    Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
    Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
    Yang JW; Choi YL
    Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
    Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
    Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients.
    Tao J; Sun D; Zhou H; Zhu J; Zhang X; Hou H
    Pathol Res Pract; 2022 Oct; 238():154074. PubMed ID: 35988354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
    Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
    Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.